Refractory Mycosis Fungoides/Sezary Syndrome Active Not Recruiting Phase 1 / 2 Trials for Mogamulizumab (DB12498)

Also known as: Mycosis fungoides/Sezary syndrome refractory / Refractory Mycosis Fungoides and Sezary Syndrome / Cutaneous T-cell lymphoma refractory

IndicationStatusPhase
DBCOND0126278 (Refractory Mycosis Fungoides/Sezary Syndrome)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04541017Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentTreatment